Business Context and Reporting Period
Universal Technical Institute, Inc. (UTI) filed this Form 8-K on December 1, 2022, to report the completion of a strategic acquisition. UTI, a Delaware corporation, finalized the purchase of Concorde Career Colleges, Inc. ("Concorde"), a provider of healthcare education programs including nursing, dental hygiene, and medical diagnostics.
Key Financial Metrics and Transaction Details
- Transaction Type: Acquisition of 100% of issued and outstanding shares of Concorde.
- Purchase Price: Base price of $50.0 million in cash, subject to customary adjustments.
- Target Profile: Concorde operates 17 campuses across eight states with approximately 8,000 students, offering in-person, hybrid, and online programs.
- Financial Statements: The filing does not provide specific revenue, profit, or cash flow figures for UTI or Concorde within the text. Audited financial statements for Concorde (year ended Dec 31, 2021) and unaudited statements (nine months ended Sept 30, 2022) are scheduled to be filed as an amendment within 71 days.
Material Changes
The primary material change is the consolidation of Concorde as a wholly-owned subsidiary of UTI. This transaction expands UTI's portfolio into healthcare education sectors. No other material changes to UTI's existing operations or financial position were disclosed in this specific report.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the closing. The filing notes that unaudited pro forma condensed combined financial statements for the year ended September 30, 2022, will be filed within 71 days to illustrate the financial impact of the acquisition. No specific forward-looking guidance, risk factors, or contingencies regarding the integration were detailed in this text.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments are applied to the $50.0 million base.
- Review the upcoming Exhibit 99.2 for Concorde's audited and unaudited financial statements to assess historical performance.
- Examine the upcoming Exhibit 99.3 for pro forma financial information to understand the combined entity's projected financial position.
- Confirm the integration timeline and any potential synergies or costs not detailed in this initial filing.